"The ePAT team is undertaking validation trials with dementia patients to support its registration with regulatory bodies such as Australia’s Therapeutic Goods Administration, the US Food and Drug Administration and EU bodies, a process likely to take up to 18 months." - Professor Jeff Hughes
MNQ Price at posting:
1.8¢ Sentiment: Buy Disclosure: Held